Perrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain
(World News Science)

DUBLIN, April 6, 2020/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it was the first to receive approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter (`OTC`) diclofenac sodium topical gel 1%. On February 14, 2020, the FDA approved Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) for nonprescription or OTC, use through its prescription (Rx)-to-OTC switch process. The product will be marketed under retailer`s store brand labels and will provide consumers with a high-quality, value alternative to GSK`s Voltaren® Arthritis Pain, which is indicated for the temporary relief of arthritis...